Why Scale a Dose by a Response Ratio?
Titration often starts with a dose that produces a response below or above its target. If the response changes in direct proportion to dose, the dose can be scaled by the ratio of the desired response to the observed response. This is appealingly simple: it uses the current dose and response, requires no separately reported slope, and predicts an exact target under the assumed model.
That last qualification matters. The ratio rule is not a general property of dose adjustment. It follows from a particular dose-response relationship and from measurements that represent the regimen being adjusted. A baseline response, nonlinear response, changing clearance, or measurement taken before pharmacokinetic equilibration can make a seemingly reasonable ratio update inaccurate. The derivation therefore begins with the model and its assumptions.
The response can be an exposure measure, a concentration measure, or another quantitative endpoint, provided the assumed relationship is appropriate. The ratio \(R^*/R_k\) is dimensionless because numerator and denominator have the same response units, so \(D_{k+1}\) retains the dose units of \(D_k\). For example, if both responses are measured in mg/L and the dose is in mg, the updated dose is still in mg.
Deriving the Rule and Its Assumptions
Suppose that, under fixed treatment conditions, response follows \(R(D)=aD\), where \(a>0\) is constant. The target dose \(D_{k+1}\) must satisfy \(aD_{k+1}=R^*\). At the current dose, the observed response satisfies \(aD_k=R_k\). Dividing the target equation by the current-dose equation eliminates the unknown proportionality constant:
This derivation is complete under the specified model: it does not require knowing \(a\), but it does require that the same \(a\) relates dose to response at both doses. The following conditions give that requirement practical meaning.
- Direct proportionality through the origin. The relevant response is \(R(D)=aD\), not \(R(D)=b+aD\) with a nonzero baseline \(b\). The response scale must have a meaningful zero for this relation.
- Stable treatment conditions. Other determinants of response are effectively unchanged between the observation and the proposed dose: for example, dose interval, route, formulation, adherence, and relevant patient state. If exposure is the response, clearance and bioavailability should not have changed materially.
- Representative measurement. The observed response should reflect the current regimen. When the endpoint depends on accumulation or delayed response, the adjustment interval must allow the relevant equilibration or response delay; otherwise \(R_k\) may reflect earlier doses or conditions.
- Positive, usable responses. The ratio requires \(R_k\ne0\), and ordinary dose scaling requires a positive response and a positive target. A zero, negative, or poorly measured denominator does not support a meaningful ratio update.
- Local and practical adequacy. The proposed dose must lie in a region where the proportional model remains credible and the response is sufficiently predictable. The formula itself does not ensure that a dose is clinically suitable.
Worked Example: Scaling a Dose to an Exposure Target
Suppose, hypothetically, that a patient receives 100 mg per dosing occasion on an unchanged schedule. After the regimen has reached the relevant steady condition, a concentration-based exposure metric is 8.0 mg/L, and the target is 10.0 mg/L. Assume this metric is directly proportional to dose under the unchanged regimen.
The proportional update is
The response predicted by the proportional model is \(8.0\ \mathrm{mg/L}\times(125/100)=10.0\ \mathrm{mg/L}\), which equals the target. The units cancel in the response ratio, leaving a dose in mg. This calculation is justified only if the observed exposure is representative and changing dose from 100 mg to 125 mg preserves the same proportional exposure relationship.
When the Raw Ratio Is Not Exact
A common alternative model has a baseline response in addition to the dose-related component: \(R(D)=b+aD\). Here the target response is not generally obtained by multiplying dose by \(R^*/R_k\), because the ratio includes the baseline \(b\) as though it also scaled with dose. If \(a\) and \(b\) are known, solving the model for the dose gives \(D_{k+1}=(R^*-b)/a\). Equivalently, using the current dose and response, \(D_{k+1}=D_k+(R^*-R_k)/a\). This is an additive correction based on the modeled slope, not raw ratio scaling.
Worked Example: A Nonzero Baseline Changes the Update
Consider hypothetical response data described by \(R(D)=2+0.08D\), where \(D\) is in mg and \(R\) is in response units. At the current dose of 50 mg, the response is \(2+0.08(50)=6\) units. The target is 8 units.
Applying the raw ratio rule gives
Using the displayed rounded dose, the model predicts \(R=2+0.08(66.67)=2+5.3336=7.3336\), or approximately 7.334 units. Thus, raw ratio scaling falls short of the 8-unit target.
Solving the affine model directly gives
At 75.0 mg, \(R=2+0.08(75.0)=8.00\) units. The intercept accounts for the difference: only the dose-related part, not the 2-unit baseline, increases with dose.
A different departure from direct proportionality is a power relationship, \(R(D)=aD^\gamma\), with \(a>0\) and \(\gamma>0\). For this model, the response ratio is \((D_{k+1}/D_k)^\gamma\), not simply \(D_{k+1}/D_k\). Solving for dose therefore gives \(D_{k+1}=D_k(R^*/R_k)^{1/\gamma}\). The raw ratio rule is the special case \(\gamma=1\).
Worked Example: Adjusting Under a Nonlinear Power Model
Suppose hypothetical data are consistent with \(R(D)=aD^{0.6}\), and a dose of 80 mg produces a response of 12.0 units. The target is 15.0 units. Assume the power model and its exponent are known to apply over the dose range being considered.
Since \(\gamma=0.6\), the model-based update is
The model predicts \(12.0(116.0/80)^{0.6}\approx15.0\) response units, subject to rounding. By contrast, raw ratio scaling would give \(80(15/12)=100\) mg. At 100 mg, the power model predicts \(12.0(100/80)^{0.6}\approx13.72\) units, below target. This comparison shows why the response model, rather than the arithmetic convenience of a ratio, determines the appropriate update.
Assumptions, Diagnostics, and Alternatives
A proportional update is easiest to defend when the response is an exposure measure known to scale linearly with dose under a fixed regimen, or when repeated data support that relationship over the range of interest. A single current dose-response pair cannot establish proportionality: it identifies the current response but does not reveal whether a baseline, curvature, saturation, or changing patient factor is present. Use model knowledge or multiple informative observations to assess the relationship.
Before using a ratio, check that the response and target are on the same scale and in the same units, that the denominator is not near zero, and that the current measurement corresponds to the stated dose. Then examine the prediction after updating. If the proportional model predicts an implausibly large response change, or if past dose-response observations do not approximately pass through the origin, the ratio rule deserves scrutiny. If replicate measurements vary substantially, an update from one noisy observation may overreact to measurement error even when the underlying model is proportional.
| Approach | Model or calculation | When it is appropriate |
|---|---|---|
| Proportional ratio | \(D_{k+1}=D_k(R^*/R_k)\) | Response is directly proportional to dose through zero under stable conditions. |
| Additive, affine-model correction | \(D_{k+1}=D_k+(R^*-R_k)/a\) for \(R=b+aD\) | A nonzero baseline is present and the slope \(a\) is suitably known. |
| Model-based inverse | Choose \(D_{k+1}\) by solving \(R(D_{k+1})=R^*\) | A suitable nonlinear or other specified dose-response model is available. |
These alternatives are not interchangeable recipes: each relies on a different response model. If a model is poorly estimated, its inverse may be just as unreliable as an unjustified ratio. Where the model is uncertain, the update should be treated as a prediction to evaluate, not as proof that the target will be achieved.
Common Mistakes and Limitations
- Assuming every response scales with dose. The wrong reasoning is “the target is 25% higher, so the dose must be 25% higher.” That conclusion follows only when response is directly proportional to dose under unchanged conditions. An intercept or nonlinear relationship changes the required dose.
- Using a response from the wrong treatment state. A measurement collected before the relevant equilibration, after missed doses, or under a changed regimen may not represent the response to \(D_k\). The ratio then compares quantities that do not correspond to the same model conditions.
- Ignoring measurement uncertainty. The formula treats \(R_k\) as informative about the underlying response. If measurement error is large, especially when \(R_k\) is small, the ratio can be highly variable. Replication, model-based estimation, or a cautious clinical review may be needed.
- Confusing an exact model result with a guaranteed clinical outcome. Under \(R(D)=aD\), the calculated dose reaches the target in the model. Individual variability, adherence, changing physiology, and model misspecification can make the realized response differ.
The proportional rule does not itself specify dose limits, rounding, safety checks, or how to respond to delayed observations. It also does not resolve whether the chosen target is clinically appropriate. Those are separate design decisions. Its specific contribution is narrower: when the direct proportionality assumptions hold, it converts a response ratio into a dose ratio with a transparent derivation.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- A hypothetical 40 mg dose produces a response of 5.0 units. Under a directly proportional model, what dose targets 6.5 units?
- Why can raw ratio scaling fail when response follows \(R(D)=b+aD\) with \(b\ne0\)?
- Under \(R(D)=aD^2\), a current response is 9 units at 30 mg. What dose does the model predict for a target response of 16 units?
- Name two conditions that can make a measured response unsuitable for a proportional update, even if the underlying dose-response relationship is proportional.
Solutions. (1) \(40(6.5/5.0)=52.0\) mg. (2) The response ratio includes the baseline \(b\), although that baseline does not increase with dose; solve the affine model instead. (3) Here \(\gamma=2\), so \(D_{k+1}=30(16/9)^{1/2}=40.0\) mg. (4) Examples include measuring before the relevant equilibration, a changed dosing interval or formulation, nonadherence, or a substantial change in a patient factor that affects response.